Senior Director, Commercial Drug Product Manufacturing Operations

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$244K-$305K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$102,662 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.4% - Faster than average

167% above the BLS role benchmark for product management aggregate.

Matched to SOC 11-1021 - Product Management aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Product From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Director, Commercial Drug Product Manufacturing Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Commercial Drug Product Manufacturing Operations will lead commercial drug product manufacturing and primary packaging activities within the Drug Product Development & Manufacturing organization. The role will oversee execution of commercial manufacturing operations across external manufacturing and packaging partners to support reliable commercial supply and lifecycle management. Responsibilities include commercial readiness activities, site qualification, technology transfer, process validation, PPQ execution, post-approval changes, troubleshooting, continued process verification (CPV), and operational excellence initiatives. The role will also support execution of commercial process monitoring activities to ensure sustained process performance and product quality. Responsibilities: - Lead execution of commercial manufacturing and primary packaging operations across CMOs and packaging partners. - Lead implementation of post-approval manufacturing and packaging changes. - Lead execution of continued process verification (CPV) activities across commercial manufacturing operations. - Manage monitoring and trending of critical process parameters, process

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.